The Effect of Prednisone on Histologic and Gross Characteristics in Canine Mast Cell Tumors

Overview

Journal Can Vet J

Specialty Veterinary Medicine

Date 2021 Jan 4

PMID 33390598

Citations 5

Authors

Ken J Linde

Stephen L Stockdale

Michael B Mison

James A Perry

Affiliations

Soon will be listed here.

Abstract

The objective of the study was to determine whether neoadjuvant prednisone therapy affects histological features of cutaneous and subcutaneous mast cell tumors. Twenty-eight dogs with a treatment naïve > 1-cm diameter mast cell tumor (MCT) were randomly assigned (Random number generator; Random.org, Dublin, Ireland) in a blinded fashion to receive either prednisone or placebo (Quality Food Center Pharmacy, Kirkland, Washington, USA). Volumes of mast cell tumors were calculated before incisional and excisional biopsies. Following incisional biopsy, patients received either prednisone (1 mg/kg body weight) daily or a placebo for 7 to 14 days leading up to excisional biopsy. Tumor grade for cutaneous MCT, and mitotic count and atypia for all tumors were reported. Perioperative treatment with prednisone had no significant effect on tumor grade, atypia, or mitotic count. Tumor volume was significantly decreased with prednisone treatment. The use of neoadjuvant prednisone to decrease MCT volume in order to facilitate tumor excision, can be considered without significant concern for change of tumor histologic features in the common population of low- to intermediate-grade MCT.

Citing Articles

Prognostic significance of YKL-40 expression in canine cutaneous mast cell tumors.

Kuo C, Huang W, Yang S, Chang Y, Chang H, Jeng C BMC Vet Res. 2024; 20(1):537.

PMID: 39614259 PMC: 11605933. DOI: 10.1186/s12917-024-04385-1.

Tumor Grade and Mitotic Count Are Prognostic for Dogs with Cutaneous Mast Cell Tumors Treated with Surgery and Adjuvant or Neoadjuvant Vinblastine Chemotherapy.

Anderson K, Pellin M, Snyder E, Clarke D Vet Sci. 2024; 11(8).

PMID: 39195818 PMC: 11360381. DOI: 10.3390/vetsci11080363.

Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.

Brown G, Finlay J, Straw R, Ziea J, Leung B, OConnell K Front Vet Sci. 2022; 9:1003165.

PMID: 36387404 PMC: 9643212. DOI: 10.3389/fvets.2022.1003165.

Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Klahn S, Dervisis N, Lahmers K, Benitez M Vet Sci. 2022; 9(6).

PMID: 35737330 PMC: 9227510. DOI: 10.3390/vetsci9060277.

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

De Nardi A, Horta R, Fonseca-Alves C, Noleto de Paiva F, Linhares L, Firmo B Cells. 2022; 11(4).

PMID: 35203268 PMC: 8870669. DOI: 10.3390/cells11040618.

References

Abadie J, Amardeilh M, Delverdier M . Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc. 2003; 215(11):1629-34. View

Patnaik A, Ehler W, MacEwen E . Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984; 21(5):469-74. DOI: 10.1177/030098588402100503. View

Dos Santos Horta R, Eunice Lavalle G, Narducci Monteiro L, Alves Dos Reis F, de Padua Costa M, Giuliano A . Evaluation of Histological, Immunohistochemical, Clinical and Genetic Prognostic Factors Associated with the Response of Canine Mast Cell Tumours to Glucocorticotherapy. J Comp Pathol. 2018; 165:72-81. DOI: 10.1016/j.jcpa.2018.10.001. View

Weisse C, Shofer F, Sorenmo K . Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc. 2002; 38(1):71-3. DOI: 10.5326/0380071. View

Bostock D, Crocker J, Harris K, Smith P . Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer. 1989; 59(6):915-8. PMC: 2246742. DOI: 10.1038/bjc.1989.193. View

Shaw T, Kudnig S, Firestone S . Diagnostic accuracy of pre-treatment biopsy for grading cutaneous mast cell tumours in dogs. Vet Comp Oncol. 2017; 16(2):214-219. DOI: 10.1111/vco.12346. View

McCaw D, Miller M, Ogilvie G, Withrow S, Brewer Jr W, Klein M . Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med. 1994; 8(6):406-8. DOI: 10.1111/j.1939-1676.1994.tb03259.x. View

Teng S, Hsu W, Chiu C, Wong M, Chang S . Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Vet J. 2012; 193(2):551-6. DOI: 10.1016/j.tvjl.2012.01.033. View

Elston L, R Sueiro F, Cavalcanti J, Metze K . The importance of the mitotic index as a prognostic factor for survival of canine cutaneous mast cell tumors: a validation study. Vet Pathol. 2009; 46(2):362-4, author reply 364-5. DOI: 10.1354/vp.46-2-362. View

10.

Romansik E, Reilly C, Kass P, Moore P, London C . Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol. 2007; 44(3):335-41. DOI: 10.1354/vp.44-3-335. View

11.

Thompson J, Yager J, Best S, Pearl D, Coomber B, TORRES R . Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Vet Pathol. 2010; 48(1):169-81. DOI: 10.1177/0300985810390716. View

12.

Seguin B, Besancon M, McCallan J, Dewe L, Tenwolde M, Wong E . Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med. 2006; 20(4):933-40. DOI: 10.1892/0891-6640(2006)20[933:rrcoac]2.0.co;2. View

13.

Giantin M, Granato A, Baratto C, Marconato L, Vascellari M, Morello E . Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication?. PLoS One. 2014; 9(4):e95481. PMC: 3991658. DOI: 10.1371/journal.pone.0095481. View

14.

Krick E, Billings A, Shofer F, Watanabe S, Sorenmo K . Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol. 2009; 7(2):130-8. DOI: 10.1111/j.1476-5829.2009.00185.x. View

15.

Simoes J, Schoning P, Butine M . Prognosis of canine mast cell tumors: a comparison of three methods. Vet Pathol. 1994; 31(6):637-47. DOI: 10.1177/030098589403100602. View

16.

Sledge D, Webster J, Kiupel M . Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection. Vet J. 2016; 215:43-54. DOI: 10.1016/j.tvjl.2016.06.003. View

17.

Brocks B, Neyens I, Teske E, Kirpensteijn J . Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study. Vet Surg. 2008; 37(5):472-8. DOI: 10.1111/j.1532-950X.2008.00412.x. View

18.

Matsuda A, Tanaka A, Amagai Y, Ohmori K, Nishikawa S, Xia Y . Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells. Vet Immunol Immunopathol. 2011; 144(3-4):321-8. DOI: 10.1016/j.vetimm.2011.08.013. View

19.

Donnelly L, Mullin C, Balko J, Goldschmidt M, Krick E, Hume C . Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. Vet Comp Oncol. 2013; 13(1):70-6. DOI: 10.1111/vco.12021. View

20.

Kiupel M, Webster J, Bailey K, Best S, DeLay J, Detrisac C . Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2010; 48(1):147-55. PMC: 8369849. DOI: 10.1177/0300985810386469. View